CD1-MR1 2017* Peripheral blood MAIT cells are activated and reduced in frequency during human hantavirus infection (#76)
5:30 PM
HIV-1 Vpu and Nef proteins interfere with MR1 surface expression (#78)
5:30 PM
MPLA vaccine adjuvant induces group 1 CD1 protein expression on human monocytes (#80)
5:30 PM
Progressive Simian-Human Immunodeficiency Virus (SHIV) infection alters expression of key surface and transcriptional proteins on macaque MAIT cells (#82)
5:30 PM
Mucosal associated invariant T (MAIT) cells in experimental and clinical sepsis. (#84)
5:30 PM
Interleukin-7 as a potential therapeutic strategy to reconstitute MAIT cells (#86)
5:30 PM
Mycobacterium tuberculosis mycolic acid lipid tails govern GEM T cell responses (#88)
5:30 PM
Characterizing β-Mannosylceramide presented by CD1d (#90)
5:30 PM
Human CD1c-autoreactive T cells recognize monoacylglycerol and diverse self lipids using an ‘absence of interference’ mechanism (#92)
5:30 PM
CD1b presents Borrelia burgdorferi glycolipid to human T cells. (#94)
5:30 PM
Sortase-A-based strategy for the analysis of CD1d-associated lipids (#96)
5:30 PM
Serum albumin delivers LPC to DCs resulting in enhanced autoreactive activation of human iNKT cells (#98)
5:30 PM
Chemical insights and new antigens for MAIT cell activation (#100)
5:30 PM
Unravelling the molecular mechanisms of how MR1 presents a pathogen metabolic signature to MAIT cells (#102)
5:30 PM
Innate lymphoid cells modulate iNKT cell immunity (#104)
5:30 PM
The role of MR1 isoforms in antigen presentation to MAIT cells (#106)
5:30 PM
Vitamin A-Mediated Regulation of CD1 Expression During Human Dendritic Cell Differentiation (#108)
5:30 PM
Role of cellular actin in CD1d-mediated antigen presentation (#110)
5:30 PM
Identification of novel modulators of MR1 trafficking using a gene trap screen in haploid cells (#112)
5:30 PM
Role of mucosal-associated invariant T cells in lupus pathogenesis. (#114)
5:30 PM
Ex Vivo expansion of iNKT cells for adoptive cell therapy. (#116)
5:30 PM
A role of AhR signaling in NKT cell immunotherapy (#118)
5:30 PM
Th1 biased iNKT-cell activation as an effective anti-tumor response (#120)
5:30 PM
Regulatory T cells increased in advanced head and neck cancer patients suppress NKT cell function and correlate with disease progression (#122)
5:30 PM
Profiling human innate-like T cells in cancer and checkpoint blockade (#124)
5:30 PM
Interrogating the VEGF immunosuppressive axis in ovarian cancer (#126)
5:30 PM
Harnessing unconventional T cells and their targets for immunotherapy with high affinity bi-specific TCRs (#128)
5:30 PM
Ether-linked phosphatidylserine species as novel mammary tumor-enriched antigens for type II NKT cells (#130)
5:30 PM
Therapeutic reprogramming of the tumor microenvironment by iNKT cells (#132)
5:30 PM
The role of CD1d in intestinal tumor development (#134)
5:30 PM
NKT cell-targeted cancer vaccine mediating long-term memory responses and strong antitumor activity (#136)
5:30 PM
TCR-engineered iNKT cells directed towards tumour-associated antigens for cancer immunotherapy (#138)
5:30 PM
Depletions of invariant natural killer T cells in blood and omentum from patients with upper gastrointestinal cancer (#140)
5:30 PM
Exploring the evolutionary relevance of MHC class I-like molecules and innate-like T cells in tumor immunity. (#142)
5:30 PM
A new distinct MHC class I-like restricted invariant T cell lineage at the forefront of mycobacterial immunity uncovered by reverse genetics in the amphibian Xenopus (#144)
5:30 PM
Identification and thymic development of human autoreactive iNKT cells (#146)
5:30 PM
MAIT and NKT cell development is controlled by the same pathways and results in identical transcriptional programs (#148)
5:30 PM
NKT TCR domains unrelated to ligand binding instruct the thymic development of an adipose resident subset (#150)
5:30 PM
A novel population of liver-associated innate-like PLZF+CD8ααTCRαβ T cells with immune regulatory properties (#152)
5:30 PM
Characterisation of the biochemical signature regulating interaction between CD8aa and the liver expressed non-classical MHC molecule, H2-Q10 (#154)
5:30 PM
PLZF regulates effector differentiation of gd T cells (#156)
5:30 PM
Assessment of global chromatin accessibility in peripheral iNKT cell subsets (#158)
5:30 PM
Deciphering how invariant NKT cells establish tissue residency in mucosal tissue during neonatal development (#160)
5:30 PM
Elucidation of Antibacterial Functions of MAIT Cells in Human Lung Mucosa: A Transcriptomics Study (#162)
5:30 PM
Human mucosal-associated invariant T (MAIT) cells in inflamed tissues (#164)
5:30 PM
Circulating Mucosal-Associated Invariant T Cells are Reduced in Obesity (#166)
5:30 PM
A Novel Mouse Model of iNKT Cell-deficiency Generated by CRISPR/Cas9 Technology Reveals a Pathogenic Role of iNKT Cells in Metabolic Disease. (#170)
5:30 PM
Identification of Adipose Tissue Factors that Induce Regulatory iNKT Cells (#172)
5:30 PM
iNKT cells catalyze a potent and sustained IL-1β secretion pathway. (#174)
5:30 PM
Development of novel therapeutic strategy for heart failure via activating invariant natural killer T cells (#176)
5:30 PM
Aronia berry consumption inhibits T cell adoptive transfer colitis in mice by modulating Th17 and Treg populations (#178)
5:30 PM
The association between mucosal associated invariant T (MAIT) cells and liver graft quality (#180)
5:30 PM
LFA-1 signaling drives TCR- and cytokine-independent IFNγ production by innate T-lymphocytes (#182)
5:30 PM
Capturing the tissue-resident CD1a-reactive T cell population from human skin (#184)
5:30 PM
Natural killer T cells promote cholestatic liver disease in bile duct ligated mice (#186)
5:30 PM
CD1a presentation of endogenous antigens by group 2 innate lymphoid cells (#188)
5:30 PM
Function of MR1-Restricted Mucosal-Associated Invariant T Cells during Citrobacter rodentium infection (#190)
5:30 PM
Characterizing MAIT cells in human mucosal cancers (#192)
5:30 PM